In a study of 42 patients with stage IV, relapsed, or refractory NKTCL, the SMILE (L-asparaginase, methotrexate, ifosfamide, etoposide, and dexamethasone) regimen significantly improved response rates and survival compared with CHOP34. This evidence concerns the gene ASPG and extranodal nasal NK/T cell lymphoma.